GSK has completed its acquisition of Affinivax, which develops next-generation pneumococcal vaccines. GSK paid an upfront payment of $2.1 billion, and will pay about $1.2 billion more after certain development milestones are reached.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept